Clinical and genetic characteristics of the total cohort and according to applied postremission therapy
| . | Total cohort . | AlloHSCT . | AutoHSCT . | no HSCT . | P value . |
|---|---|---|---|---|---|
| Characteristics | n = 124 | n = 32 | n = 20 | n = 72 | |
| Age, y | |||||
| Median (range) | 44 (16-60) | 40 | 41 | 45 | .12 |
| Sex, no. (%) | |||||
| Male | 66 (53%) | 21 (66%) | 12 (60%) | 33 (46%) | .15 |
| Female | 58 (47%) | 11 (34%) | 8 (40%) | 39 (54%) | |
| WBC, x 109/l | |||||
| Median (range) | 32 (2-248) | 16 (2-174) | 36 (3-157) | 34 (2-248) | .23 |
| Missing | 1 | 1 | |||
| Platelets, x109/l | |||||
| Median (range) | 41 (4-319) | 39 (11.282) | 47 (10-115) | 40 (4-319) | .42 |
| Missing | 3 | 3 | |||
| Bone marrow blasts, (%) | |||||
| Median (range) | 75 (7-100) | 71 (7-99) | 77 (31-99) | 75 (25-100) | .54 |
| Missing | 5 | 1 | 4 | ||
| Type of AML, no. (%) | |||||
| De novo AML | |||||
| M0 | 6 (5%) | 1 (3%) | 5 (7%) | .24 | |
| M1 | 45 (36%) | 10 (31%) | 9 (45%) | 26 (36%) | |
| M2 | 54 (44%) | 16 (50%) | 6 (30%) | 32 (44%) | |
| M4 | 6 (5%) | 2 (6%) | 2 (10%) | 2 (3%) | |
| M5 | 2 (2%) | 1 (3%) | 1 (5%) | ||
| M6 | 1 (1%) | 1 (5%) | |||
| Unclassified | 1 (1%) | 1 (1%) | |||
| Missing | 9 (7%) | 2 (6%) | 1 (5%) | 6 (9%) | |
| Cytogenetics, no, (%) | |||||
| Normal karyotype | 92 (74%) | 21 (66%) | 14 (70%) | 57 (79%) | .32 |
| Molecular characteristics no., (%) | |||||
| FLT3-internal tandem duplications | 11 (9%) | 5 (16%) | 1 (5%) | 5 (7%) | .38 |
| NPM1 | 2 (2%) | 1 (3%) | 1 (1%) | .67 | |
| Missing | 1 | 1 |
| . | Total cohort . | AlloHSCT . | AutoHSCT . | no HSCT . | P value . |
|---|---|---|---|---|---|
| Characteristics | n = 124 | n = 32 | n = 20 | n = 72 | |
| Age, y | |||||
| Median (range) | 44 (16-60) | 40 | 41 | 45 | .12 |
| Sex, no. (%) | |||||
| Male | 66 (53%) | 21 (66%) | 12 (60%) | 33 (46%) | .15 |
| Female | 58 (47%) | 11 (34%) | 8 (40%) | 39 (54%) | |
| WBC, x 109/l | |||||
| Median (range) | 32 (2-248) | 16 (2-174) | 36 (3-157) | 34 (2-248) | .23 |
| Missing | 1 | 1 | |||
| Platelets, x109/l | |||||
| Median (range) | 41 (4-319) | 39 (11.282) | 47 (10-115) | 40 (4-319) | .42 |
| Missing | 3 | 3 | |||
| Bone marrow blasts, (%) | |||||
| Median (range) | 75 (7-100) | 71 (7-99) | 77 (31-99) | 75 (25-100) | .54 |
| Missing | 5 | 1 | 4 | ||
| Type of AML, no. (%) | |||||
| De novo AML | |||||
| M0 | 6 (5%) | 1 (3%) | 5 (7%) | .24 | |
| M1 | 45 (36%) | 10 (31%) | 9 (45%) | 26 (36%) | |
| M2 | 54 (44%) | 16 (50%) | 6 (30%) | 32 (44%) | |
| M4 | 6 (5%) | 2 (6%) | 2 (10%) | 2 (3%) | |
| M5 | 2 (2%) | 1 (3%) | 1 (5%) | ||
| M6 | 1 (1%) | 1 (5%) | |||
| Unclassified | 1 (1%) | 1 (1%) | |||
| Missing | 9 (7%) | 2 (6%) | 1 (5%) | 6 (9%) | |
| Cytogenetics, no, (%) | |||||
| Normal karyotype | 92 (74%) | 21 (66%) | 14 (70%) | 57 (79%) | .32 |
| Molecular characteristics no., (%) | |||||
| FLT3-internal tandem duplications | 11 (9%) | 5 (16%) | 1 (5%) | 5 (7%) | .38 |
| NPM1 | 2 (2%) | 1 (3%) | 1 (1%) | .67 | |
| Missing | 1 | 1 |
Subheadings under “de novo AML” refer to French American British classification subtypes.
WBC, white blood cell count; FLT3-ITD, FLT3 internal tandem duplication; neg, negative; NPM1, nucleophosmin 1; WBC, white blood cell count; wt, wild-type.